The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Open accessAbstract
In December 2005, sorafenib became the first new treatment to be approved for advanced renal cancer in more than a decade. Wilhelm and colleagues provide the history of this drug, which inhibits several kinases involved in tumour signalling and angiogenesis. Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) — from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 — was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedThe Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Self-citationTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
CELLULAR ONCOGENES AND RETROVIRUSES
Bishop, J. M. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.001505 · Cited by 1,641
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Research works printed but not linked: 27
- Niman, H. L. Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor. Nature 307, 180–183 (1984). · doi:10.1038/307180a0
- McPhillips, F. et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br. J. Cancer 85, 1753–1758 (2001). · doi:10.1054/bjoc.2001.2139
- Riedl, B. et al. Potent Raf kinase inhibitors from the diphenylurea class: structure activity relationships. Clin. Cancer Res. 20, 83a (2001).
- Smith, R. A. et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett. 11, 2775–2778 (2001). · doi:10.1016/s0960-894x(01)00571-6
- Wilhelm, S. et al. BAY 43-9006, a novel Raf-1 kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells. Proc. Am. Assoc. Cancer Res. 42, 923 (2001).
- Chang, Y. S. et al. BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Clin. Cancer Res. 46, 5831 (2005).
- Liu, L. et al. Sorafenib (BAY 43-9006) inhibits the Raf/MEK/ERK pathway in hepatocellular carcinoma (HCC) cells and produces robust efficacy against PLC/PRF/5 HCC tumors in mice. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
- Kupsch, P. et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5, 188–196 (2005). · doi:10.3816/ccc.2005.n.030
- Flaherty, K. T. et al. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: PFS and response versus B-Raf status. Proc. 4th Intl. Symp. Targeted Anticancer Ther. Amsterdam, The Netherlands [online] , (2006).
- Awada, A. et al. A Phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with Taxotere in patients with advanced solid tumors. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Geneva, Switzerland (2004).
- Steinbild, S. et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J. Clin. Oncol. 23, 3115 (2005). · doi:10.1200/jco.2005.23.16_suppl.3115
- Eisen, T. et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J. Clin. Oncol. 23, 7508 (2005). · doi:10.1200/jco.2005.23.16_suppl.7508
- Gollob, J. et al. Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma. Eur. J. Cancer Supplements 3, 226 (2005).
- Robert, C. et al. Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. Eur. J. Cancer Supplements 3, 254 (2005).
- Escudier, B. et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur. J. Cancer Supplements 3, 226 (2005). Pivotal Phase III trial confirming sorafenib's significant PFS benefit and acceptable tolerability in patients with advanced refractory RCC. These findings formed the basis of sorafenib's recent FDA approval for this indication.
- Abou-Alfa, G. K. et al. Phase II biomarker analysis of sorafenib (BAY 43-9006) in patients with advanced hepatocellular carcinoma. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
- Gatzemeier, U. et al. Phase II trial of single-agent sorafenib in patients with advanced non-small-cell lung carcinoma. J. Clin. Oncol. 24, 364s (2006). · doi:10.1200/jco.2006.24.18_suppl.7002
- Steinbild, S. et al. Phase II study of sorafenib (BAY43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research — EWIV (CESAR). J. Clin. Oncol. 24, 144s (2006). · doi:10.1200/jco.2006.24.18_suppl.3094
- Dahut, W. L. et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J. Clin. Oncol. 24, 218s (2006). · doi:10.1200/jco.2006.24.18_suppl.4506
- Moreno-Aspitia, A. et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J. Clin. Oncol. 24, 577 (2006). · doi:10.1200/jco.2006.24.18_suppl.577
- Lorigan, P. et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J. Clin. Oncol. 24, 8012 (2006). · doi:10.1200/jco.2006.24.18_suppl.8012
- Sosman, J. et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J. Clin. Oncol. 24, 128s (2006). · doi:10.1200/jco.2006.24.18_suppl.3031
- Elting, J. et al. Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. Proc. Am. Assoc. Cancer Res. 47, A2909 (2006).
- Advani, A. S. C-kit as a target in the treatment of acute myelogenous leukemia. Curr. Hematol. Rep. 4, 51–58 (2005).
- Chen, L. L. et al. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep. 7, 293–299 (2005). · doi:10.1007/s11912-005-0053-6
- Blumenschein, G. R. et al. Phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in relapsed or refractory advanced non-small cell lung cancer. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
- Levy, J. et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc. Am. Assoc. Cancer Res. 47, 213–214 (2006).
Cited by
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Yang, W. S., & Stockwell, B. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.010 · Cited by 1,876
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Photopolymerization in 3D Printing
Bagheri, A., & Jin, J. (2019) · ACS Applied Polymer Materials · doi:10.1021/acsapm.8b00165 · Cited by 1,436
Insufficient Sleep in Adolescents and Young Adults: An Update on Causes and Consequences
Owens, J., ADOLESCENT SLEEP WORKING GROUP, COMMITTEE ON ADOLESCENCE, Au, R., Carskadon, M., Millman, R., Wolfson, A., Braverman, P. K., Adelman, W. P., Breuner, C. C., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1696 · Cited by 1,413
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Ferroptosis, a new form of cell death, and its relationships with tumourous diseases
Yu, H., Guo, P., Xie, X., Wang, Y., & Chen, G. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13008 · Cited by 710
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Zhu, Y.-J., Zheng, B., Wang, H.-Y., & Chen, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.5 · Cited by 702
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Duncton, M. A. J. (2011) · MedChemComm · doi:10.1039/c1md00134e · Cited by 607
Hsin, K.-Y., Ghosh, S., & Kitano, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083922 · Cited by 606
Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Targeting the MAPK pathway in KRAS-driven tumors
Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.004 · Cited by 497
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis
Gao, R., Kalathur, R. K. R., Coto‐Llerena, M., Ercan, C., Buechel, D., Shuang, S., Piscuoglio, S., Dill, M. T., Camargo, F. D., Christofori, G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114351 · Cited by 484
Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma
Keating, G. M., & Santoro, A. (2009) · Drugs · doi:10.2165/00003495-200969020-00006 · Cited by 482
Induced pluripotent stem cells — opportunities for disease modelling and drug discovery
Grskovic, M., Javaherian, A., Strulovici, B., & Daley, G. Q. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3577 · Cited by 474
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Hepatocellular carcinoma review: Current treatment, and evidence-based medicine
Raza, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4115 · Cited by 464
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 414
Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103811 · Cited by 379
Resistance to BRAF-targeted therapy in melanoma
Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 374
Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y.-Y., Granter, S. R., Chin, L., & Cantley, L. C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.026 · Cited by 359
Comprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
From genes to drugs: targeted strategies for melanoma
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3218 · Cited by 354
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Ross, J. S., Wang, K., Chmielecki, J., Gay, L., Johnson, A., Chudnovsky, J., Yelensky, R., Lipson, D., Ali, S. M., Elvin, J. A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.29825 · Cited by 351
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 335
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Dar, A. C., Das, T. K., Shokat, K. M., & Cagan, R. L. (2012) · Nature · doi:10.1038/nature11127 · Cited by 333
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
Chen, K.-F., Chen, H.-L., Tai, W.-T., Feng, W.-C., Hsu, C.-H., Chen, P.-J., & Cheng, A.-L. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175786 · Cited by 317
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 311
Sorafenib: A Review in Hepatocellular Carcinoma
Keating, G. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0484-7 · Cited by 308
Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 307
Mir, O., Coriat, R., Blanchet, B., Durand, J.-P., Boudou-Rouquette, P., Michels, J., Ropert, S., Vidal, M., Pol, S., Chaussade, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037563 · Cited by 304
Cancer invasion and metastasis: changing views
Duffy, M., McGowan, P., & Gallagher, W. (2008) · The Journal of Pathology · doi:10.1002/path.2282 · Cited by 302
Recent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293
“Both Kobe0065 and Kobe2602 at 20 μM efficiently inhibited the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing H-Ras, although the effect was slightly weaker than that of 2 μM sorafenib (11), an inhibitor of multiple protein kinases including Raf (Fig.”
BackgroundMethodSelectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., & Brossart, P. (2008) · Blood · doi:10.1182/blood-2007-02-075945 · Cited by 288
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
Wörsdörfer, P., Dalda, N., Kern, A., Krüger, S., Wagner, N., Kwok, C. K., Henke, E., & Ergün, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-52204-7 · Cited by 272
VEGF receptor protein–tyrosine kinases: Structure and regulation
Roskoski, R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.121 · Cited by 269
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
Conn, V. M., Chinnaiyan, A. M., & Conn, S. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00721-7 · Cited by 258
Modeling the expansion of virtual screening libraries
Lyu, J., Irwin, J. J., & Shoichet, B. K. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01234-w · Cited by 193
Sorafenib: a clinical and pharmacologic review
Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496453 · Cited by 169
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
PARK, G. B., CHOI, Y., KIM, Y. S., LEE, H.-K., KIM, D., & HUR, D. Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2252 · Cited by 96
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models
Mariniello, B., Rosato, A., Zuccolotto, G., Rubin, B., Cicala, M. V., Finco, I., Iacobone, M., Frigo, A. C., Fassina, A., Pezzani, R., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0337 · Cited by 63
Miyake, H., Kurahashi, T., Yamanaka, K., Kondo, Y., Muramaki, M., Takenaka, A., Inoue, T.-A., & Fujisawa, M. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.08.011 · Cited by 54
Ding, Z., Dong, Z., Chen, Z., Hong, J., Yan, L., Li, H., Yao, S., Yan, Y., Yang, Y., Yang, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733530 · Cited by 47
(2010) · PubMed Central · Cited by 46
Du, G., Rao, S., Gurbani, D., Henning, N. J., Jiang, J., Che, J., Yang, A., Ficarro, S. B., Marto, J. A., Aguirre, A. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01502 · Cited by 39
Clavreul, A., Pourbaghi-Masouleh, M., Roger, E., Lautram, N., Montero-Menei, C. N., & Menei, P. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0605-2 · Cited by 35
Paradoxical activation of c-Src as a drug-resistant mechanism
Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31
Yu, Z., Feng, H., Zhuo, Y., Li, M., Zhu, X., Huang, L., Zhang, X., Zhou, Z., Zheng, C., Jiang, Y., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00546-0 · Cited by 27
“Sorafenib acts as a multi-kinase inhibitor and is widely used in HCC [35].”
BackgroundYoon, J.-S., & Lee, C.-W. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00883-0 · Cited by 14
Metadata
- Authors
- Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-10-01
- Volume
- 5
- Issue
- 10
- Pages
- 835-844
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2061345986
- Cited by
- 1,829
- References
- 69
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.